Free Newsletter
Boosting protein levels guards against Parkinson's
Creating a mouse that churned out twice the normal levels of a protein called Nrf2 protected them from Parkinson's disease, according to a new study published in the Proceedings of the National Academy of Sciences. Even after injecting the mice with a chemical known to trigger Parkinson's, the researchers say the mice were completely immune to the disease, which afflicts some 1.5 million Americans.
This new research follows recent reports that higher levels of Nrf2 can delay ALS, or Lou Gehrig's disease. And follow-up studies are being conducted to see if higher protein levels can also fight Alzheimer's and Huntington's disease. Nrf2 is produced by brain cells called astrocytes. And the theory is that astrocyte dysfunction may be the root cause of all these diseases.
"It's becoming apparent that astrocyte dysfunction is a major contributing factor to the neurons dying," Jeffrey Johnson, a professor in pharmaceutical sciences at the University of Wisconsin who led the study, told the AFP. "If we can make the astrocyte better or stronger, or so that it doesn't become dysfunctional, you can preserve the neurons."
- check out the AFP report
Related Articles:
An old drug promises to slow aging process
Protein therapies could delay aging process
Skin cells used to treat neurodegenerative disease
Gene therapy offers impressive results for Parkinson's
Molecule could reverse Parkinson's
Stem cell transplant a success against Parkinson's
Comments
Excellent conclusion and the cell degeneration in Parkinson’s and other degenerative diseases can be stopped by elimination the modified proteins. This is an easier alternative to keep the interactome working in the cells - contact Axanton
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: